| Carl N Griffin, DO | |
|
6908 E Reno Ave, Midwest City, OK 73110-2128 | |
| (405) 737-7000 | |
| (405) 737-7700 |
| Full Name | Carl N Griffin |
|---|---|
| Gender | Male |
| Speciality | Family Medicine |
| Location | 6908 E Reno Ave, Midwest City, Oklahoma |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1548365117 | NPI | - | NPPES |
| 200102570A | Medicaid | OK | |
| 73-0804209 | Other | OK | TAX ID |
| 730804209001 | Other | OK | BC GROUP NUMBER |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 03095 (Oklahoma) | Primary |
| 207PE0004X | Emergency Medicine - Emergency Medical Services | 3095 (Oklahoma) | Secondary |
| Entity Name | Adair County Health Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972780765 PECOS PAC ID: 9638065907 Enrollment ID: O20040224000664 |
News Archive
Oracle Corp., the primary developer behind Oregon's dysfunctional health insurance website, sued Cover Oregon and accused Gov. John Kitzhaber of conducting a "smear campaign" against the company. Meanwhile, Massachusetts officials decided to replace that state's failed exchange with another from a private company, rather than shifting to the federal marketplace.
Medical device safety researchers are calling on the Food and Drug Administration to release hundreds of thousands of hidden injury and malfunction reports related to about 100 medical devices.
Tioga Pharmaceuticals, a clinical stage biotechnology company, today announced the initiation of a Phase 2 clinical study of asimadoline, a novel, well-studied kappa-opioid receptor specific agonist, for the treatment of pruritus or itching. The double-blind, placebo-controlled clinical study is designed to evaluate the safety, tolerability, and clinical efficacy of asimadoline in patients with pruritus due to atopic dermatitis and is being conducted at 20 clinical study centers in the United States.
"Researchers have identified a mysterious new disease that has left scores of people in Asia and some in the United States with AIDS-like symptoms even though they are not infected with HIV," the Associated Press reports.
› Verified 9 days ago
| Entity Name | Creek Nation Hospital & Clinics |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366593923 PECOS PAC ID: 5698786226 Enrollment ID: O20070821000130 |
News Archive
Oracle Corp., the primary developer behind Oregon's dysfunctional health insurance website, sued Cover Oregon and accused Gov. John Kitzhaber of conducting a "smear campaign" against the company. Meanwhile, Massachusetts officials decided to replace that state's failed exchange with another from a private company, rather than shifting to the federal marketplace.
Medical device safety researchers are calling on the Food and Drug Administration to release hundreds of thousands of hidden injury and malfunction reports related to about 100 medical devices.
Tioga Pharmaceuticals, a clinical stage biotechnology company, today announced the initiation of a Phase 2 clinical study of asimadoline, a novel, well-studied kappa-opioid receptor specific agonist, for the treatment of pruritus or itching. The double-blind, placebo-controlled clinical study is designed to evaluate the safety, tolerability, and clinical efficacy of asimadoline in patients with pruritus due to atopic dermatitis and is being conducted at 20 clinical study centers in the United States.
"Researchers have identified a mysterious new disease that has left scores of people in Asia and some in the United States with AIDS-like symptoms even though they are not infected with HIV," the Associated Press reports.
› Verified 9 days ago
| Entity Name | Spectrum Healthcare Solutions, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558816850 PECOS PAC ID: 7618255118 Enrollment ID: O20161104000192 |
News Archive
Oracle Corp., the primary developer behind Oregon's dysfunctional health insurance website, sued Cover Oregon and accused Gov. John Kitzhaber of conducting a "smear campaign" against the company. Meanwhile, Massachusetts officials decided to replace that state's failed exchange with another from a private company, rather than shifting to the federal marketplace.
Medical device safety researchers are calling on the Food and Drug Administration to release hundreds of thousands of hidden injury and malfunction reports related to about 100 medical devices.
Tioga Pharmaceuticals, a clinical stage biotechnology company, today announced the initiation of a Phase 2 clinical study of asimadoline, a novel, well-studied kappa-opioid receptor specific agonist, for the treatment of pruritus or itching. The double-blind, placebo-controlled clinical study is designed to evaluate the safety, tolerability, and clinical efficacy of asimadoline in patients with pruritus due to atopic dermatitis and is being conducted at 20 clinical study centers in the United States.
"Researchers have identified a mysterious new disease that has left scores of people in Asia and some in the United States with AIDS-like symptoms even though they are not infected with HIV," the Associated Press reports.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Carl N Griffin, DO Po Box 269064, Oklahoma City, OK 73126-9064 Ph: (405) 231-3857 | Carl N Griffin, DO 6908 E Reno Ave, Midwest City, OK 73110-2128 Ph: (405) 737-7000 |
News Archive
Oracle Corp., the primary developer behind Oregon's dysfunctional health insurance website, sued Cover Oregon and accused Gov. John Kitzhaber of conducting a "smear campaign" against the company. Meanwhile, Massachusetts officials decided to replace that state's failed exchange with another from a private company, rather than shifting to the federal marketplace.
Medical device safety researchers are calling on the Food and Drug Administration to release hundreds of thousands of hidden injury and malfunction reports related to about 100 medical devices.
Tioga Pharmaceuticals, a clinical stage biotechnology company, today announced the initiation of a Phase 2 clinical study of asimadoline, a novel, well-studied kappa-opioid receptor specific agonist, for the treatment of pruritus or itching. The double-blind, placebo-controlled clinical study is designed to evaluate the safety, tolerability, and clinical efficacy of asimadoline in patients with pruritus due to atopic dermatitis and is being conducted at 20 clinical study centers in the United States.
"Researchers have identified a mysterious new disease that has left scores of people in Asia and some in the United States with AIDS-like symptoms even though they are not infected with HIV," the Associated Press reports.
› Verified 9 days ago
Tracy Adelle Kidwell, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1800 S Douglas Blvd, Midwest City, OK 73130 Phone: 405-741-7722 Fax: 405-741-7757 | |
Dr. Robert Allan Dickey, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2801 Parklawn Dr, Suite 101, Midwest City, OK 73110 Phone: 405-737-6691 Fax: 405-737-7723 | |
Ryan M Biggers, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1212 S Douglas Blvd, Midwest City, OK 73130 Phone: 405-736-6811 Fax: 405-736-6863 | |
Dr. Wesley Williams, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1636 Midtown Pl, Midwest City, OK 73130 Phone: 405-869-7700 | |
Dr. Joshua Scott Smith, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 8800 Se 15th St, Midwest City, OK 73110 Phone: 405-739-6840 | |
Nathan Valentine, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 7521 Se 15th St, Midwest City, OK 73110 Phone: 405-453-8004 Fax: 405-561-4857 | |
Dr. Michael Terry Anderson, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 8800 Se 15, Midwest City, OK 73110 Phone: 405-739-6840 Fax: 405-455-3087 |